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The preamble of Directive 2001/83/EC 
stipulates that prescribers and pharmacists 
must have access to neutral, objective sources 
of information about products available 
on the market.2 The Pharmaceutical Forum 
(2007) presents ten core quality principles 
on information to patients on diseases and 
treatment options.  These are objective 
and unbiased information, evidence-based, 
reliable, accessible, relevant and appropriate, 
patient oriented, up to date, understandable, 
transparent, and consistent with statutory 
information.3 Coulter and Ellins (2007) argue 
that a number of patient focused quality 
interventions can be taken to engage patients 
in their own or their family’s individual care, 
including improving health literacy, clinical 
decision-making, self-care and patient safety.4
One of the objectives of the Medicines 
Authority is to provide objective and unbiased 
information on medicinal products. This is done 
in a number of ways including the evaluation 
of the labelling on medicinal products, 
approval of the information on the patient 
information leaﬂet (PIL) and of the Summary 
of Product Characteristics (SPC) and the 
publication of the list of authorised medicines 
and the approved PIL and SPC on its website.  
The Authority set a communications 
strategy and activities were planned.  The 
ﬁrst priority was to make information 
about medicines accessible to healthcare 
professionals and to patients and consumers.  
In 2010-2011 a speciﬁc national set of 
initiatives entitled ‘Know Your Medicines’ 
which were mainly targeted at patients and 
consumers were carried out. The initiatives 
were aimed at informing patients and 
consumers about medicines thus supporting 
and empowering them to participate in 
decisions for the choice of their medicines 
and to use their medicines rationally. The 
initiatives were based on a need analysis 
carried out between September 2010 and 
January 2011.
An analysis of public knowledge 
and use of medicines
A needs analysis was carried out with 
the aim of identifying the public’s knowledge 
about medicines, awareness on the medicines 
lifecycle, trust in medicines and awareness 
on choice and use of medicines. Two hundred 
telephone interviews were conducted over a 
period of ﬁve months, between September 
2010 and January 2011.  A stratiﬁed sample of 
ﬁve hundred people was used based on gender, 
age and locality. Therefore the response rate 
was of 40%. The interviews were conducted 
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Public health authorities regulate in the public interest to protect 
health, ensure patient access to safe medicines, stimulate innovation 
and encourage a competitive market.1  Pharmaceutical regulation 
supports various components of a national pharmaceutical policy, 
including research and development (through regulation of clinical 
trials and provision of scientiﬁc advice), authorisation of medicinal 
products, regulation of the supply chain (manufacturers, wholesale 
dealers and pharmacies), pharmacovigilance and  the rational use of 
medicinal products (through information about medicinal products 
and the use of medicines). The tangible public health outcomes of 
these processes are access, availability and affordability of medicinal 
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between 08.00am and 08.00pm to ensure 
that working participants are also reached. 
 
The research showed that 66% of 
participants seek advice or information 
before taking non-prescription medicine 
for the ﬁrst time while 12% never seek 
advice or information. 91% of participants 
mostly trust the doctor as a source of 
information on medicines, whilst 5% mostly 
trust the pharmacist. A total of 58% of 
participants claim to seek information on 
non-prescription medicines from doctors, 
29% from pharmacists and 6% from the 
internet.   Almost half of participants 
responded that they always read the package 
leaﬂet before taking a non-prescription 
medicine for the ﬁrst time, 14% frequently 
read the package leaﬂet, 22% read it 
sometimes and 14% never read the package 
leaﬂet mainly because the information 
is provided by the doctor or pharmacist.  
Over 85% of participants do not know the 
difference between innovator and generic 
medicines.  71% of those who use the 
internet graded it as a ‘very good’ or ‘good’ 
source of information on medicines.  41% of 
respondents who use the internet said that 
the information which they get from the 
internet affects which treatment/medicine 
they buy. A small percentage (3%) of 
respondents said that they bought medicine 
over the internet, claiming wider selection, 
convenience and price as the main reasons 
for doing this, while 8% of respondents 
said that they are not concerned about the 
authenticity or safety of medicines available 
for sale on the internet.  With regards to 
storage of medicines, 75% of participants 
declared that they store medicines in humid 
places such as kitchens and bathrooms.
Activities carried out as part of the 
communications strategy 
The results of the study were assessed 
to ensure that the information provided 
and the initiatives undertaken are in line 
with the needs of the general population. 
A National Initiative entitled ‘Know Your 
Medicines’ was launched in January 2011 to 
support healthcare professionals, patients 
and consumers on the choice and use of 
medicines. The initiatives included:
1. The development of the Malta Medicines 
List (www.maltamedicineslist.com) as 
a source of information on all authorised 
medicines.  The list includes advance 
searching and ﬁltering functionalities 
and links to Summary of Product 
Characteristics and Package Leaﬂets.
2. A speciﬁc webpage with targeted 
information for patients and consumers 
(www.knowyourmedicines.com).  Both 
websites will be integrated in a new 
website on medicines with enhanced 
features.
3. Active participation in traditional media 
through articles, interviews and programs 
and the use of social online (e.g. 
Facebook) to reach different age groups.
4. Two widely distributed information 
leaﬂets in Maltese and English languages. 
One of the leaﬂets has a question and 
answer format in line with the gaps 
identiﬁed through the needs analysis and 
another leaﬂet presented information on 
innovator and generic medicines and a 
section on falsiﬁed medicines. 
5. Development of a Know Your Medicines 
Helpline.
6. SMS and e-mail notiﬁcations for 
information related to safety and quality 
of medicines.
7. Delivery of continuous professional 
development sessions for pharmacists 
organised by the Malta College of 
Pharmacy Practice and participation in 
sessions for pharmacists organised by the 
Malta Chamber of Pharmacists.
8. Collaboration with other regulators and 
the Consumers Affairs Council to organise 
information sessions speciﬁcally targeted 
to consumers.
9. Information meetings about legislation 
in collaboration with the Malta EU Action 
Steering Committee.
10. Papers for local and international journals, 
including an article on the ﬁrst Seven 
Years of EU Pharmaceutical Legislation 
in Malta on the WHO Drug Information 
Journal.5
Way forward
The Medicines Authority will continue with 
the implementation of its communications 
strategy and the next step is the provision of 
targeted information based on the needs of 
speciﬁc stakeholders (healthcare professionals, 
patients and consumers and industry). A new 
website incorporating advanced features 
and with information targeted for different 
stakeholder groups will be launched in the 
following months. Moreover the initiatives 
taken to date will be evaluated. 
The Medicines Authority is grateful to all 
health care professionals and associations for 
their collaboration, particularly in reviewing 
and distributing the information material.  
Feedback and recommendations for further 
development and for future communication 
and information initiatives is welcome. 
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Key points
s  4HE -EDICINES !UTHORITY HAS A PUBLIC HEALTH REMIT TO PROVIDE OBJECTIVE AND UNBIASED 
information on medicinal products.
s  ! TOTAL OF  OF PARTICIPANTS OF A STUDY CONDUCTED BY THE -EDICINES !UTHORITY SEEK 
advice or information before taking non-prescription medicine for the ﬁrst time while 
12% never seek advice or information. Over 85% of participants do not know the 
difference between innovator and generic medicines.  Most participants use the internet 
as a source of information on medicines and 3% of respondents said that they bought 
medicine over the internet, claiming wider selection, convenience and price as the main 
reasons for doing this.  
s  4HE -EDICINES !UTHORITY LAUNCHED THE @+NOW 9OUR -EDICINES )NITIATIVES TO EMPOWER 
patients and consumers and support healthcare professionals in the choice and use of 
medicines. 
